{
    "id": 16642,
    "fullName": "SQSTM1 - NTRK1",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SQSTM1-NTRK1 results from the fusion of SQSTM1 and NTRK1 (PMID: 26565381). SQSTM1-NTRK1 has not been biochemically characterized, however, it has demonstrated sensitivity to a Trk inhibitor (PMID: 26565381).",
            "references": [
                {
                    "id": 4304,
                    "pubMedId": 26565381,
                    "title": "Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26565381"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 8878,
        "geneSymbol": "SQSTM1",
        "terms": [
            "SQSTM1",
            "A170",
            "DMRV",
            "FTDALS3",
            "NADGP",
            "OSIL",
            "p60",
            "p62",
            "p62B",
            "PDB3",
            "ZIP3"
        ]
    },
    "variant": "SQSTM1 - NTRK1",
    "createDate": "01/15/2016",
    "updateDate": "11/27/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 4914,
                "geneSymbol": "NTRK1",
                "terms": [
                    "NTRK1",
                    "MTC",
                    "p140-TrkA",
                    "TRK",
                    "Trk-A",
                    "TRK1",
                    "TRKA"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 3985,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical study, a lung adenocarcinoma patient with a SQSTM1-NTRK1 fusion experienced a prolonged response to Rozlytrek (entrectinib) (PMID: 26565381).",
            "molecularProfile": {
                "id": 16921,
                "profileName": "SQSTM1 - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4304,
                    "pubMedId": 26565381,
                    "title": "Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26565381"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13819,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a pediatric patients with congenital fibrosarcoma harboring SQSTM1-NTRK1 fusion (PMID: 29606586; NCT02637687).",
            "molecularProfile": {
                "id": 16921,
                "profileName": "SQSTM1 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 8418,
                "name": "congenital fibrosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11285,
                    "pubMedId": 29606586,
                    "title": "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29606586"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15291,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a combined analysis of three trials, Vitrakvi (larotrectinib) treatment resulted in partial response in two patients with advanced solid tumors harboring a SQSTM1-NTRK1 fusion (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431).",
            "molecularProfile": {
                "id": 16921,
                "profileName": "SQSTM1 - NTRK1"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10867,
                    "pubMedId": 29466156,
                    "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29466156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6730,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rozlytrek (entrectinib) treatment resulted in overall partial response and complete response in the brain in a non-small cell lung carcinoma patient harboring SQSTM1-NTRK1 fusion, who remained on study at 10 months (AACR Apr 2016, Abstract # CT007).",
            "molecularProfile": {
                "id": 16921,
                "profileName": "SQSTM1 - NTRK1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5790,
                    "pubMedId": null,
                    "title": "Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-na\u00efve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=4abd89d1-63f0-4e65-b91c-486888d54e7a&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 16921,
            "profileName": "SQSTM1 - NTRK1",
            "profileTreatmentApproaches": [
                {
                    "id": 19324,
                    "name": "Larotrectinib",
                    "profileName": "SQSTM1 - NTRK1"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}